• 1
    Vidor E, Fritzell B, Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection 1996; 24:447458.
  • 2
    Lea AP, Balfour JA. Virosormal hepatitis A vaccine (Strain RG-SB). BioDrugs 1997; 7:232248.
  • 3
    Nalin DR. VAQTA. Drugs of the Future 1995; 20:2429.
  • 4
    Clemens R, Safary A, Hepburn A, et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; (171(Suppl 1):S44S49.
  • 5
    Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453457.
  • 6
    Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. J Am Med Assoc 1994; 271:13281334.
  • 7
    Prikazsky V, Olear V, Cernoch A, et al. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 1994; 44:457459.
  • 8
    McMahon BJ, Beller M, Williams J, et al. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 1996; 150:733739.
  • 9
    Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and longterm antibody persistence. J Med Virol 1994; 44:446451.
  • 10
    Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996; 49:235241.
  • 11
    Totos G, Gizaris V, Papaevangelou G. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination. Vaccine 1997; 15:12521253.
  • 12
    Maiwald H, Jilg W, Bock HL, et al. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 1997; 15:346348.
  • 13
    Wiedermann G, Kundi M, Ambrosch F, et al. Inactivated hepatitis A vaccine: long term antibody persistence. Vaccine 1997; 15:612615.
  • 14
    Wiedermann G, Ambrosch F, André FE, et al. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 1992; 10(Suppl):S129S131.
  • 15
    Goilav C, Zuckerman J, Lafrenz M, et al. Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study. J Infect 1997; 34:158.
  • 16
    Berger R, Just M. Vaccination against hepatitis A: control 3 years after the first vaccination. Vaccine 1992; 10:295.
  • 17
    Van Damme P, Thoelen S, Cramm M, Meheus A. Safety and immunogenicity of a high-potency inactivated hepatitis A vaccine. J Travel Med 1996; 3:8390.
  • 18
    Holzer BR, Hatz C, Schmidt-Sissolak D, et al. Immunogenicity and adverse effects of inactivated virosome versus alumadsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 1996; 14:982986.
  • 19
    Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis-A vaccine. Lancet 1994; 343:322324.
  • 20
    Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, et al. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 1995; 13:891893.
  • 21
    Frosner GG, Overby LR, Flehmig B, et al. Serological investigation of patients and family contacts in an epidemic of hepatitis A. J Med Virol 1977; 1:163173.
  • 22
    Miller WJ, Clark W, Hurni WM, et al. Sensitive assays for hepatitis-A antibodies. J Med Virol 1993; 41:201204.
  • 23
    Schmidtke P, Habermehl P, Knuf M, et al. Kinetics of hepatitis A virus (HAV)-specific humoral and cell mediated immunity after vaccination. Abstract 586, Infectious Diseases Society of America meeting, San Fransisco, September 1997.
  • 24
    Chen XQ, Boland GJ, Van Hattum J, De Gast GC. T cell response to HAV after hepatitis A vaccination. Hepatology 1997; (in press).